End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.83 MYR | -0.60% | +2.47% | -7.78% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Analyst opinion has improved significantly over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- Low profitability weakens the company.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Most analysts recommend that the stock should be sold or reduced.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-7.78% | 1.39B | B | ||
+11.84% | 27.79B | B+ | ||
-32.98% | 2.98B | B- | ||
-15.97% | 2.52B | C+ | ||
+11.90% | 2.34B | - | A- | |
-1.11% | 1.91B | B | ||
-0.38% | 1.27B | - | ||
+4.01% | 1.13B | - | ||
+13.51% | 1.12B | C | ||
-2.06% | 1.02B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- TOPGLOV Stock
- Ratings Top Glove Corporation Bhd.